
Nautilus Biotechnology Investor Relations Material
Latest events

Q1 2025
Nautilus Biotechnology
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nautilus Biotechnology Inc
Access all reports
Nautilus Biotechnology, Inc. is a life sciences company specializing in the development of a next-generation platform for proteomics research. The company's technology is designed to identify and quantify proteins with high sensitivity, aiming to advance scientific discovery and improve healthcare outcomes. Nautilus focuses on enabling researchers to study the proteome at unprecedented depth and scale, which could support advancements in drug discovery, diagnostics, and personalized medicine. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Key slides for Nautilus Biotechnology Inc


Q3 2024
Nautilus Biotechnology Inc


Q4 2024
Nautilus Biotechnology Inc
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
NAUT
Country
🇺🇸 United States